Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules

Edgewise Therapeutics (Nasdaq: EWTX) announced inducement equity grants made January 30, 2025 to seven new non‑executive employees totaling 198,250 stock options under its 2024 Inducement Equity Incentive Plan.

Rhea-AI Summary

Edgewise Therapeutics (Nasdaq: EWTX) announced inducement equity grants made January 30, 2025 to seven new non‑executive employees totaling 198,250 stock options under its 2024 Inducement Equity Incentive Plan.

Options have an exercise price of $28.15 (equal to the closing price on the grant date) and vest 25% after one year then 1/48th monthly thereafter, subject to continued service, granted pursuant to Nasdaq Listing Rule 5635(c)(4).

Argus Feb 2 session

+2.63% close to close Open Argus

Details

News Market Reaction – EWTX

On Feb 2, the day this news came out, EWTX closed 2.63% above the previous close.

Data tracked by StockTitan Argus for the Feb 2 session.

Key Figures

Current price: $28.15 Inducement option shares: 198,250 shares Number of employees: 7 employees +3 more

Current price

$28.15

Pre-news close from market context

Inducement option shares

198,250 shares

Total options granted to 7 new non-executive employees

Number of employees

7 employees

Recipients of inducement stock options

Option exercise price

$28.15 per share

Equal to EWTX closing price on January 30, 2025 grant date

Initial vesting cliff

25%

Vests on one-year employment anniversary for each employee

Ongoing vesting rate

1/48th monthly

Remaining options vest monthly after first anniversary, service-based

Historical Context

5 past events · Latest: Jan 13

5 events

1. Jan 13

   Corporate update

   24h Move

   +3.4%

   Outlined 2026 priorities, pivotal data timing, and NDA submission plans.

2. Jan 06

   Conference presentation

   24h Move

   -2.7%

   Announced J.P. Morgan conference presentation and webcast logistics.

3. Jan 05

   Inducement grants

   24h Move

   -0.8%

   Inducement stock options for new hires under 2024 Inducement Plan.

4. Dec 24

   Clinical trial data

   24h Move

   +25.5%

   Completed CIRRUS-HCM Parts B/C with favorable safety and biomarker data.

5. Dec 02

   Inducement grants

   24h Move

   -9.1%

   Single-hire inducement option grant with standard vesting terms.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

inducement stock options, exercise price, equity incentive plan, nasdaq listing rule 5635(c)(4)

4 terms

inducement stock options financial

"Edgewise granted inducement stock options to purchase a total of 198,250 shares"

Inducement stock options are grants of the company’s stock rights given to recruit or retain a specific executive or employee, often as a signing bonus instead of cash. Investors care because these awards can increase the total shares outstanding and dilute existing ownership, alter future reported expenses, and signal how the company is paying for talent; think of them as a hiring incentive paid in future company pieces rather than immediate money.

exercise price financial

"Each inducement stock option has an exercise price of $28.15 per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

equity incentive plan financial

"pursuant to Edgewise's 2024 Inducement Equity Incentive Plan (the "Inducement Plan")"

An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.

nasdaq listing rule 5635(c)(4) regulatory

"granted as inducements ... in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BOULDER, Colo., Feb. 2, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions, today announced that on January 30, 2025, Edgewise granted inducement stock options to purchase a total of 198,250 shares of Edgewise's common stock to 7 new non-executive employees in connection with the commencement of their employment, pursuant to Edgewise's 2024 Inducement Equity Incentive Plan (the "Inducement Plan").    

Each inducement stock option has an exercise price of $28.15 per share, which is equal to the closing price of a share of Edgewise common stock on the grant date, and shall vest as follows: 25% of the shares subject to such inducement stock option shall vest on the one year anniversary of the start date of each employee, and an additional one forty-eighth (1/48th) of the shares subject to such inducement stock option shall vest monthly thereafter, subject to the employee's continued service.

Each inducement award is subject to the terms of the Inducement Plan and related forms of agreements, and were granted as inducements material to these employees to enter into employment with Edgewise in accordance with Nasdaq Listing Rule 5635(c)(4). 

About Edgewise Therapeutics
Edgewise Therapeutics is a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The Company's deep expertise in muscle physiology is driving a new generation of novel therapeutics. Sevasemten is an orally administered first-in-class fast skeletal myosin inhibitor in late-stage clinical trials in Becker and Duchenne muscular dystrophies. EDG-7500 is a novel cardiac sarcomere modulator for the treatment of hypertrophic cardiomyopathy, currently in Phase 2 clinical development. EDG-15400 is a novel cardiac sarcomere modulator for the treatment of heart failure, currently in Phase 1 clinical development. The entire team at Edgewise is dedicated to our mission: changing the lives of patients and families affected by serious muscle diseases. To learn more, go to: www.edgewisetx.com or follow us on LinkedIn and X.

View original content to download multimedia:https://www.prnewswire.com/news-releases/edgewise-therapeutics-reports-inducement-grants-as-permitted-by-the-nasdaq-listing-rules-302675780.html

SOURCE Edgewise Therapeutics

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Edgewise (EWTX) announce on February 2, 2026 about inducement grants?

Edgewise announced inducement stock options totaling 198,250 shares granted January 30, 2025 to seven new non‑executive employees. According to the company, grants were made under its 2024 Inducement Equity Incentive Plan as permitted by Nasdaq Listing Rule 5635(c)(4).

How many employees received options and what was the total grant size for EWTX?

Seven new non‑executive employees received inducement awards totaling 198,250 stock options. According to the company, the grants were issued in connection with the commencement of their employment on January 30, 2025.

What are the vesting terms for the Edgewise (EWTX) inducement stock options?

Each option vests 25% on the one‑year anniversary of the employee start date, then vests an additional 1/48th monthly thereafter. According to the company, vesting is subject to the employee's continued service and plan terms.

What exercise price was set for the EWTX inducement options and how was it determined?

The exercise price for each inducement option is $28.15 per share, equal to the closing price of Edgewise common stock on the grant date. According to the company, that price reflects the market close on January 30, 2025.

Why were the inducement awards granted under Nasdaq Listing Rule 5635(c)(4) for EWTX?

The awards were granted as inducements to enter employment and were made in accordance with Nasdaq Listing Rule 5635(c)(4). According to the company, the grants were material to recruit the seven new non‑executive hires and followed the Inducement Plan.